Dendritic cells lentivirally engineered to overexpress interleukin‐10 inhibit contact hypersensitivity responses, despite their partial activation induced by transduction‐associated physical stress

Dendritic cells (DCs) constitute an attractive target for immunotherapeutic approaches. Because DCs are largely refractory to transfection with plasmid DNA, several viral transduction protocols were established. The potential side‐effects of lentiviral transduction on the phenotype and activation state of DCs left unstimulated after transduction have not been assessed. There is a need to analyse these parameters as a result of the requirement of using DCs with a low activation state for therapeutic strategies intended to induce tolerance.

[1]  M. Bros,et al.  A novel plasmid DNA electroporation method allows transfection of murine DC. , 2009, JIM - Journal of Immunological Methods.

[2]  Qizhi Tang,et al.  The Foxp3+ regulatory T cell: a jack of all trades, master of regulation , 2008, Nature Immunology.

[3]  P. Janmey,et al.  Cell mechanics: integrating cell responses to mechanical stimuli. , 2007, Annual review of biomedical engineering.

[4]  M. Dullaers,et al.  Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. , 2007, Human gene therapy.

[5]  M. Bros,et al.  Formalin-Fixed Staphylococcus aureus Particles Prevent Allergic Sensitization in a Murine Model of Type I Allergy , 2007, International Archives of Allergy and Immunology.

[6]  A. Sutter,et al.  A newly established murine immature dendritic cell line can be differentiated into a mature state, but exerts tolerogenic function upon maturation in the presence of glucocorticoid. , 2007, Blood.

[7]  J. Aerts,et al.  Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics , 2007, Gene Therapy.

[8]  M. Bros,et al.  Induction of regulatory T cells by leflunomide in a murine model of contact allergen sensitivity. , 2006, The Journal of investigative dermatology.

[9]  A. Maroof,et al.  Interleukin‐4 can induce interleukin‐4 production in dendritic cells , 2006, Immunology.

[10]  P. Morel,et al.  Polarization of naive T cells into Th1 or Th2 by distinct cytokine‐driven murine dendritic cell populations: implications for immunotherapy , 2005, Journal of leukocyte biology.

[11]  K. Shearwin,et al.  Transcriptional interference--a crash course. , 2005, Trends in genetics : TIG.

[12]  D. Larkin,et al.  Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. , 2005, Blood.

[13]  P. Robbins,et al.  Immunization with Lentiviral Vector-Transduced Dendritic Cells Induces Strong and Long-Lasting T Cell Responses and Therapeutic Immunity 1 , 2005, The Journal of Immunology.

[14]  H. Smits,et al.  Different faces of regulatory DCs in homeostasis and immunity. , 2005, Trends in immunology.

[15]  B. Neyns,et al.  Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells , 2004, The journal of gene medicine.

[16]  C. Figdor,et al.  Dendritic cell immunotherapy: mapping the way , 2004, Nature Medicine.

[17]  S. Sudowe,et al.  Transcriptional targeting of dendritic cells in gene gun-mediated DNA immunization favors the induction of type 1 immune responses. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  M. Dullaers,et al.  Lentivirally transduced dendritic cells as a tool for cancer immunotherapy , 2003, The journal of gene medicine.

[19]  T. Tüting,et al.  Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin , 2003, Gene Therapy.

[20]  P. Tiberghien,et al.  Polybrene and interleukin‐4: two opposing factors for retroviral transduction of bone‐marrow‐derived dendritic cells , 2002, The journal of gene medicine.

[21]  A. Enk,et al.  CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. , 2002, Blood.

[22]  Josephine C. Adams,et al.  Fascins, and their roles in cell structure and function. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[23]  L. Naldini,et al.  Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. , 2002, Human gene therapy.

[24]  R. Ritter,et al.  Development of a Langerhans cell-targeted gene therapy format using a dendritic cell-specific promoter , 2001, Gene Therapy.

[25]  A. Thomson,et al.  DIFFERENTIAL EFFECTS OF MYELOID DENDRITIC CELLS RETROVIRALLY TRANSDUCED TO EXPRESS MAMMALIAN OR VIRAL INTERLEUKIN-10 ON CYTOTOXIC T LYMPHOCYTE AND NATURAL KILLER CELL FUNCTIONS AND RESISTANCE TO TUMOR GROWTH1,2 , 2001, Transplantation.

[26]  A. Enk,et al.  Expression of the actin-bundling protein fascin in cultured human dendritic cells correlates with dendritic morphology and cell differentiation. , 2000, The Journal of investigative dermatology.

[27]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.

[28]  A. Reske-Kunz,et al.  The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells. , 1998, Journal of immunology.

[29]  Luigi Naldini,et al.  Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo , 1997, Nature Biotechnology.

[30]  J. Streilein,et al.  Ultraviolet B-exposed and soluble factor-pre-incubated epidermal Langerhans cells fail to induce contact hypersensitivity and promote DNP-specific tolerance. , 1997, The Journal of investigative dermatology.

[31]  Freddie H. Fu,et al.  Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. , 1996, Transplantation.

[32]  T. Starzl,et al.  Bone marrow-derived dendritic cell progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. , 1995, Transplantation.

[33]  B. Stockinger,et al.  Mechanisms of tolerance induction in major histocompatibility complex class II-restricted T cells specific for a blood-borne self-antigen , 1994, The Journal of experimental medicine.

[34]  M. Mehlig,et al.  Dendritic cells from mouse bone marrow: in vitro differentiation using low doses of recombinant granulocyte-macrophage colony-stimulating factor. , 1992, Journal of immunological methods.

[35]  T. Kikuchi.  Genetically modified dendritic cells for therapeutic immunity. , 2006, The Tohoku journal of experimental medicine.

[36]  S. Adams,et al.  Recent advances in dendritic cell biology. , 2005, Journal of clinical immunology.